Bigstock The U.S. Food and Drug Administration (FDA) has approved Tessie, a tasipimidine oral solution that is the first to be approved by the agency for the treatment of both noise aversion and separation anxiety in dogs. Noise aversion and separation anxiety are reportedly common fear-based behavioral disorders that may present with vocalization, trembling, panting, destructive behavior, gastrointestinal signs, or inappropriate elimination. Tasipimidine is an alpha-2 adrenoceptor agonist designed to reduce heightened sympathetic nervous system (fight-or-flight) activity associated with stress and anxiety, according to the FDA. The oral solution is administered approximately one hour before anticipated triggering events, such as fireworks or owner departure, and may be given up to three times within 24 hours with appropriate dosing intervals. It is advised by the agency not to give the medication with food, as it may delay the drug’s absorption. Tessie is available by prescription, reflecting the need for veterinary diagnosis and oversight as part of broader behavioral management strategies. For more information, visit the FDA website.
